- Successful growth strategy delivers sales growth in H1 of +11% versus prior year to €824m
- Strong growth momentum in the Pharma segment
- EBITDA up +41% to €127m, with margin expanding 300 bps to 15.5%.; all business units contributing
- Free cash flow €63m, +11% above 2024’s high benchmark
- H1 Book-to-Bill at 117%, signaling strong foundation for future growth
- 2025 outlook: sustained sales growth and continued margin expansion